Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.

Oncotarget · 2017 · PMC5593680 · PMID 28915708

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significancep = 0.06so close (0.05 < p ≤ 0.1)

showed a trendno p-value reported

Results showed a trend for improved OAS in patients treated with metformin vs the controls, which approached but did not reach statistical significance ( p = 0.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.